Abstract:F-18-FDG and 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) have been proven useful in diagnosing and staging many types of cancer but with emphasis on different aspects of tumor biology. The aim of the current study was to evaluate whether F-18-FDG and F-18-FLT can be used complementarily in monitoring the biologic characteristics of colorectal cancer (CRC). Methods: Human CRC cell lines SW480 and SW620 of the same genetic origin but different metastatic potential were cultured and implanted into nude mice to create CRC models. Uptake of F-18-FDG and F-18-FLT in SW480 and SW620 cells in vitro was assessed after incubation with radiotracers for 0, 30, 60, 90, and 120 min. In vivo imaging of SW480 and SW620 tumor-bearing mice was performed using small-animal PET/CT at 60 min after injection of each tracer. A region of interest was drawn over tumor and background to calculate the tumor-to-nontumor ratio (T/NT) using software on reconstructed images. Tumor growth rate, metastatic status, and survival time were assessed in tumor-bearing mice. The relationship between uptake of the tracers, metastatic capability, and tumor marker expression was evaluated using linear regression. Results: SW480 tumors grew more quickly than SW620 tumors (t = 3.332, P = 0.004). A higher incidence of lung and liver metastases was noted for SW480 than for SW620 (P = 0.023). Uptake in SW480 and SW620 cells was significantly different between F-18-FDG and F-18-FLT (t = 2.507, P = 0.021, vs. t = 3.497, P = 0.002). In the small-animal PET study, the T/NT of F-18-FDG did not differ between SW480 and SW620 tumors (2.69 +/- 0.98 vs. 3.09 +/- 1.26, P = 0.524), but the T/NT of F-18-FLT differed significantly between SW480 and SW620 tumors (3.65 +/- 0.51 vs. 2.22 +/- 0.42, P < 0.001). Heat shock protein 27 (HSP27) expression and integrin beta(3) expression were higher, whereas vascular endothelial growth factor receptor 2 (VEGFR2) expression and Ki67 expression were lower, in SW480 cells than in SW620 cells. For SW480, metastases in lung and liver correlated significantly with F-18-FLT uptake in tumors (r = 0.763, P = 0.005) and with expression of HSP27 (r = 0.894, P = 0.008) and integrin beta(3) (r = 0.635, P = 0.088). A correlation was also found between F-18-FLT uptake and expression of HSP27 (r = 0.924, P = 0.004) and integrin beta(3) (r = 0.813, P = 0.025). No correlation was found between F-18-FDG uptake in tumors and metastasis in lung and liver (r = 20.111, P = 0.388). However, there was a significantly negative correlation between F-18-FDG uptake and the survival time of tumor-bearing mice (r = 20.500, P = 0.017), to which F-18-FLT did not relate (r = 0.262, P = 0.182). Conclusion: High uptake of F-18-FDG and F-18-FLT may reflect poorer survival and a higher metastatic potential for CRC in mice. Combining F-18-FDG with F-18-FLT PET would be helpful in better predicting the biologic behavior of CRC.

Early Detection of Thymidylate Synthase Resistance in Non-Small Cell Lung Cancer with FLT-PET Imaging

18F-FDG PET/CT for the Early Prediction of the Response Rate and Survival of Patients with Recurrent or Metastatic Breast Cancer.

The Pemetrexed-Containing Treatments in the Non-small Cell Lung Cancer, is -/Low Thymidylate Synthase Expression Better Than +/high Thymidylate Synthase Expression? A Meta-analysis

Dexamethasone Pretreatment Impairs the Thymidylate Synthase Inhibition Mediated Flare in Thymidine Salvage Pathway Activity in Non-Small Cell Lung Cancer

Abstract 3049: Dexamethasone pretreatment impairs the TS inhibition-mediated flare in thymidine salvage pathway activity

Pemetrexed induces ROS generation and cellular senescence by attenuating TS‐mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC

Fluorodeoxyglucose Positron Emission Tomography and Chemotherapy-Related Tumor Marker Expression in Non-Small Cell Lung Cancer

18F-Fludrodeoxyglucose Maximal Standardized Uptake Value and Metabolic Tumor Burden Are Associated with Major Chemotherapy-Related Tumor Markers in NSCLC Patients

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice

Effect of Pemetrexed Plus Platinum for Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer

99Mtc-3Prgd2 SPECT/CT Imaging for Monitoring Early Response of EGFR-TKIs Therapy in Patients with Advanced-Stage Lung Adenocarcinoma

Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis.

[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors

Predictive value of 18F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1

Using Dual-Tracer PET to Predict the Biologic Behavior of Human Colorectal Cancer.

18 F-FDG PET/CT for Evaluation of Metastases in Nonsmall Cell Lung Cancer on the Efficacy of Immunotherapy.

Apoptosis Imaging Probe Predicts Early Chemotherapy Response In Preclinical Models: A Comparative Study With F-18-Fdg Pet

Dynamic 18F-FDG Total body PET Imaging as a predictive marker of induction chemo-immunotherapy response in locally advanced non-small cell lung cancer.

Evaluating [18F]FDG and [18F]FLT Radiotracers as Biomarkers of Response for Combined Therapy Outcome in Triple-Negative and Estrogen-Receptor-Positive Breast Cancer Models

Apoptosis Imaging with 18F-Ml-10 Micropet/Ct for Early Prediction of Response to Treatment in A Human Pancreatic Tumor Xenograft Model